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Introduction: Due to the frequent use of neck ultrasonography, the incidence of differentiated thyroid
microcarcinoma (DTMC), deﬁned as a lesion with greatest dimension 1 cm, is increasing worldwide.
Although DTMC generally has a lower aggressivity and a better prognosis than differentiated thyroid
carcinoma (DTC), some cases of clinically aggressive DTMC were found. The aim of this study is to
compare the rate of recurrence in DTMC and DTC, during a 3-year follow-up.
Methods: Patients with differentiated thyroid carcinoma, who underwent total thyroidectomy and
postoperative 131I-RAI ablation, were stratiﬁed according to lesion diameter (DTC for diameter > 1 cm or
DTMC  1 cm). After surgery, patients underwent a 3-year follow-up. Recurrent disease was deﬁned on
the basis of positive biochemical (Tg > 2 ng/ml under TSH-suppression or after rhTSH-stimulation) and/
or imaging (US, WBS, CT, PET/CT) ﬁndings.
Results: 449 patients have been included in the ﬁnal analysis. Linfoadenectomy rate and RAI ablative
dose were signiﬁcantly higher in DTC than in DTMC (32.7% vs. 22.4%, p ¼ 0.018 and112.3 ± 21 vs.
68.3 ± 24.1 mCi, p < 0.001). During the follow-up, 50 carcinoma recurrences occurred, more frequent in
DTC than in DTMC (15.6% vs. 7.6%, p ¼ 0.010). After adjustment for gender, age, rate of lymph node
dissection and 131I dose of RAI treatment, the difference in the risk of recurrence was no longer sig-
niﬁcant among DTC and DTMC patients (HR: 1.585, 95% CI 0874e2877, p ¼ 0.130).
Conclusions: The prediction of disease severity cannot be based exclusively on lesion diameter. A more
careful therapeutic approach and follow-up should be recommended in DTMC patients.
© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Differentiated thyroid carcinoma (DTC) accounts for about 95%
of the endocrine tumors [1], with a mortality rate of 0.5/100.000
cases [2] and persistence/recurrence of the disease of 15e27% [3,4].
DTC has a multifactorial etiology, that includes environmental
factors (low-iodine areas, ionizing radiations, family history of
thyroid cancer, female sexual hormones) and genetic factors (BRAF,
RET/PTC, RAS, PAX8/PPARg) [5]. According to the World Health
Organization classiﬁcation system for thyroid tumors, differenti-
ated thyroid microcarcinoma (DTMC) is deﬁned as a differentiated
thyroid carcinoma measuring 10 mm in its greatest dimensionpaper.
f of Surgical Associates Ltd.[6]. The incidence of DTMC is increasing worldwide [7e9], along
with the frequent use of neck ultrasonography (US) [10,11]. Some
data suggest that DTMC has a lower aggressivity and has a better
prognosis than DTC [11]. However, some DTMC cases were found to
be clinically aggressive and the local recurrence rate is widely
variable in different literature reports [12]. Accordingly, there is not
common agreement about DTMC's treatment. ATA's recommen-
dation for the treatment of low-risk, unifocal intrathyroidal papil-
lary microcarcinoma, without cervical lymph nodes metastasis, is
lobectomy; however, in presence of multifocality, contralateral or
distant metastasis, family history of DTC or earlier neck region
irradiation, it is recommended to perform total or near-total thy-
roidectomy [13]. Nevertheless, since some DTMC show an aggres-
sive behavior, several studies suggest total thyroidectomy in patient
with DTMC [14e18]. Radioactive iodine-131 (RAI) treatment is
performed after surgery to remove any iodine-avid residue and to
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risk patients (lesion with greatest dimension 1 cm, surgical rad-
icality, classical variant of papillary thyroid carcinoma), RAI ablation
is not indicated as it has not effective beneﬁt [13]. However, recent
studies showmany patients affected by DTMC and not treated with
RAI have an increased recurrence risk [19]. Given the high vari-
ability in literature recommendations, we performed this study
with the speciﬁc aim to compare the rate of recurrence in DTMC
and DTC, during a 3-years follow-up.2. Methods
Between 2002 and 2007, 449 consecutive patients, were
enrolled in our study; they had histological diagnosis of differen-
tiated thyroid carcinoma and underwent total thyroidectomy (with
or without linfoadenectomy) and postoperative RAI ablation.
Study population has been stratiﬁed according to lesion major
diameter as DTC in the presence of a lesion diameter >1 cm, or
DTMC for lesion diameter 1 cm.
Lesions were classiﬁed based on focality (unifocal/multifocal)
and according to pTNM staging (Tumour Node Metastasis, AJCC
Cancer Staging Manual, Seventh Edition), which evaluates param-
eters such as lesion diameter, capsular invasion, extrathyroidal
structures extension, presence of lymph node metastases at diag-
nosis, as well as ATA classiﬁcation system [13]. Moreover it was
recorded if they underwent lymphadenectomy of the central
compartment (level VI), as well as of lymph node levels II, III and IV.
All enrolled patients underwent post-operative RAI ablation with
131I and received TSH-suppressive therapy with L-thyroxine (L-T4).
After 6e12 months from thyroidectomy, all patients underwent
a complete assessment including clinical, biochemical and instru-
mental examination. During the follow-up, in all patients labora-
tory tests were performed on venous blood samples with an
electrochemiluminescence immunoassay (Elecsys E170, Roche Di-
agnostics, Mannheim). TSH (0.3e4.2 mU/ml), FT3 (2.0e4.4 pg/ml),
FT4 (0.9e1.7 ng/dl), Tg (0e50 ng/ml), Tg-Abs (0e115 IU/ml) levels
were measured at baseline and after stimulation with recombinant
human TSH (rhTSH). The hormone assay was practiced with the
patient fasted for at least 8 h and before taking the daily dose of L-
T4. Patients received two injections of 0.9 mg of rhTSH in two
consecutive days with Tg measurement on the ﬁfth day, in accor-
dance with standard protocols [20]. Since the presence of Tg-AbsTable 1
Clinical and demographic characteristics of the study population.
Whole sample (n ¼ 449)
Age e yearsa 41.9 ± 13.6
Male gender e n (%) 102 (22.7)
Mean diameter e mm 13.3 þ 9.1
Histological type- n (%)
Papillary (common type) 291 (64.8)
Follicular variant 87 (19.4)
Sclerosing variant 11 (2.4)
Tall cell variant 5 (1.1)
Follicular (common type) 53 (11.8)
Hurtle cell variant 2 (0.4)
Multifocal lesions e n (%) 101 (22.5)





Lymphadenectomy e n (%) 121 (26.9)
RAI dose e mCia 87.8 ± 32.2
p  0.05 was considered statistically signiﬁcant.
DTC: differentiated thyroid carcinoma; DTMC: differentiated thyroid microcarcinoma.
a Mean value ± standard deviation.
b KolmogoroveSmirnov Test.interferes with Tg assay, patients were always checked for the
presence of Tg-Abs high levels in order to avoid false positive or
false negative results.
A positive stimulated Tg at follow-up was deﬁned by a value
>2 ng/ml in the absence of Tg-Abs.
As imaging assessment, all patients underwent periodic neck
US, performed by the same operator and using the same instru-
ment (Esaote MyLab 25), with a probe from 8 to 10 MHz.
Tg under TSH-suppressive L-T4 therapy and US were evaluated
throughout the follow-up period at 6e12 months intervals; while
stimulated Tg was measured in all patients at 1 year from RAI
therapy and was repeated when necessary. WBS, computed to-
mography (CT) and ﬂuorodeoxy-D-glucose-positron emission to-
mography/CT (FDG-PET/CT) were performed when indicated,
usually when the Tg was elevated and neck US was negative.
Recurrent disease was deﬁned on the basis of positive
biochemical (Tg under TSH-suppression or after rhTSH-
stimulation) and/or imaging (US, WBS, CT, PET/CT) ﬁndings.
Statistical analysis was performed with the SPSS 16 system
(SPSS Inc., Chicago, IL, USA). Continuous data were expressed as
mean ± SD; categorical variables were expressed as %. In case of
values with a skewed distribution, KolmogoroveSmirnov test was
used to compare means. The chi-square test was employed to
analyze categorical data. When the minimum expected value was
<5, the Fisher's exact test was used.
A KaplaneMeier survival model (with the Log-Rank test) was
adopted to evaluate the cumulative disease-free survival according
to the type of carcinoma (DTC vs. DTMC) and each patient has been
censored at the time of the ﬁrst recurrence. To adjust for all the
other variables found to be associated with disease-free status at
univariate analyses and to evaluate the risk of disease recurrence in
DTC and DTMC, a COX regression analysis (stepwise method) was
adopted. Multi-collinearity effect in multivariable regression
models was excluded by a stepwise approach with each variable
included for p < 0.05 and excluded for p > 0.1. All the results are
presented as 2-tailed values with statistical signiﬁcance if p
values < 0.05.3. Results
449 patients (102 males and 347 females) have been included in
the ﬁnal analysis of the study, after excluding 23 patients because ofDTC (n ¼ 199) DTMC (n ¼ 250) p
42.6 ± 13.7 41.8 ± 13.6 0.609
49 (24.6) 53 (21.2) 0.428
20.8 þ 8.9 7.3 þ 2.2 <0.001b
130 (65.3) 161 (64.4) 0.934
35 (17.6) 52 (20.8)
5 (2.5) 6 (2.4)
3 (1.5) 2 (0.8)
25 (12.6) 28 (11.2)
1 (0.5) 1 (0.4)
53 (26.6) 48 (19.2) 0.069
147 (73.9) 231 (92.4) <0.001
37 (18.6) 15 (6.0)
11 (5.5) 2 (0.8)
4 (2.0) 2 (0.8)
65 (32.7) 56 (22.4) 0.018
112.3 ± 21.6 68.3 ± 24.1 <0.001
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outcome.
The demographics, clinical features and risk stratiﬁcation for
each of the 449 patients included in this study are presented in
Table 1.
Patients with DTC and DTMCwere entirely comparable formean
age and gender distribution. In contrast, as expected, the mean
diameter of lesions was higher in DTC than in DTMC patients
(20.8 ± 8.9 vs. 7.26 ± 2.23 mm, p < 0.001).
All patients underwent a total thyroidectomy and a concomitant
lymph node lateral compartment dissection was performed in 65
patients (32.7%) of DTC and in 56 patients (22.4%) of DTMC
(p ¼ 0.018).
Most patients had histological diagnosis of papillary carcinoma
(65.3% DTC and 64.4% DTMC) and no statistical difference was
found in the prevalence of different histological type among DTC
and DTMC patients.
The presence of multifocal lesions was reported by 26.6% of
cases in DTC and 19.2% in DTMC, without a signiﬁcant difference
between the two groups.
Patients with DTC showed a more advanced stage of thyroid
carcinoma than DTMC patients (p < 0.001). The risk of recurrence
according to the 3-level stratiﬁcation suggested by the ATAwas low
for 69.8% of DTC and for 87.2% of DTMC patients, intermediate for
24.1% of DTC and for 12.8% of DTMC patients, and high for 6% of DTC
and for none of DTMC patients (p < 0.001).
After surgery DTC patients received a higher mean 131I RAI
ablative dose compared with DTMC subjects (112.3 ± 21.6 mCi vs.
68.3 ± 24.1 mCi, p < 0.001).
During the follow-up, 50 carcinoma recurrences occurred. The
overall mean survival time was 1.86 ± 1.0 years in the study pop-
ulation without any signiﬁcant difference among DTC and DTMC
patients (p ¼ 0.187). The diagnosis of carcinoma recurrence was
more frequent in DTC than in DTMC (15.6% vs. 7.6%, p ¼ 0.010).
In addition, as showed in Table 2, also other variables resulted
signiﬁcantly different among patients experiencing recurrence and
those not. In particular, the prevalence of lymph node resection and
131I RAI dose were signiﬁcantly different between the two groups,
further supporting the association of these parameters with a
negative prognosis.
To adjust results for the potential confounding effect due to
these variables, we performed a multivariate analysis which
showed that, after adjustment for gender, age, rate of lymph node
dissection and 131I dose of RAI treatment, the difference in the risk
of recurrence was no longer signiﬁcant among DTC and DTMC
patients (HR: 1.585, 95% CI 0874e2877,p ¼ 0.130).Table 2







Age e yearsa 42.2 ± 13.0 40.2 ± 17.8 0.352
Male gender e n (%) 86 (21.6) 16 (32.0) 0.108
NO Follicular e n (%) 143 (35.8) 15 (30.0) 0.438
Diameter >1 cm e n (%) 168 (42.1) 31 (62.0) 0.010
Multifocal lesions e n (%) 89 (22.3) 12 (24.0) 0.857
Stage e n (%)
1 342 (85.7) 36 (72.0) 0.090
2 42 (10.5) 10 (20.0)
3 10 (2.5) 3 (6.0)
4 5 (1.3) 1 (2.0)
Lymphadenectomy e n (%) 95 (23.8) 26 (52.0) <0.001
RAI dose e mCia 85.3 ± 30.8 109.5 ± 35.8 <0.001
p  0.05 was considered statistically signiﬁcant.
a Mean value ± standard deviation.4. Discussion
In the present study we evidence that DTMC can show an
aggressive behavior; in fact we demonstrate that, after adjustment
for all potential confounding variables, DTC patients share a similar
risk of recurrence with those affected by DTMC.
Several data suggest that DTMC should be usually associated
with a favorable prognosis. Indeed, DTMC is commonly considered
a low risk lesion and, according to some authors and in agreement
with American Thyroid Association (ATA) guidelines [13], it needs a
more conservative treatment. However, there is not wide agree-
ment about this issue and contrasting opinions are currently
available about the treatment and follow-up of DTMC [10,21e23].
Our results, in line with some other evidences [24], shows that
the risk of metastasis and recurrence cannot be excluded in DTMC
patients, suggesting a more accurate treatment and follow-up in
these patients.
In the present study, we report a higher prevalence of some
major predictors of carcinoma recurrence in DTC patients. In detail,
the TNM stage as well as the administered RAI dose were higher in
DTC than in DTMC, clearly suggesting a more aggressive behavior at
diagnosis. However, one of the major feature of the TNM stage and
a relevant determinant of the RAI dose is represented by the vol-
ume of the lesion. In addition, a further element that might suggest
a more accurate treatment and follow-up in DTC is the involvement
of lymph node. Indeed, it is noteworthy to highlight that some
literature data suggest that in the presence of an involvement of >5
lymph nodes, there is a 19% increase in the risk of recurrence [25].
In our experience, although the rate of lymphadenectomy (indica-
tive of a possible lymph node involvement) is higher in DTC, it is
signiﬁcant also in DTMC group. Moreover, some further signs
associated with a negative prognosis have been found also in
DTMC. Speciﬁcally, the rate of multifocality is comparable between
DTC and DTMC and this clearly suggest a similar potential of local
invasion.
In line with these hypotheses, in our study we found a not
negligible overall rate of recurrence in DTMC (7.6%) and, at the
multivariate analysis, we demonstrated that, after adjusting for
gender, age, rate of lymphadenectomy and 131I RAI dose, the risk of
recurrence was similar in DTC and DTMC patients.
The clinical impact of these results could be of great relevance.
According to our experience, total thyroidectomy seems to be a
valid therapeutic option both in terms of reduction of the risk of
recurrence and in terms of quality of follow-up. Indeed only with
the complete resection of the thyroid gland, Tg can be used as a
marker of carcinoma recurrence [26]. In addition, although total
thyroidectomy is not without complications, it allows to avoid
resurgery in the most cases and, therefore, to reduce the total
number of complications and the psychological aversion of patients
toward a second-neck operation [27,28]. Thus, the risk/beneﬁt ratio
it is clearly in favor of the total thyroidectomy, since operative
morbidity is lower in total thyroidectomy than in partial one, and
surgery complications are similar whether performing a conser-
vative or a radical intervention [28].
5. Conclusions
In conclusion, our study clearly evidence that, although DTC is
more aggressive than DTMC, the risk of recurrence in this latter
clinical condition is not negligible. Thus, a more careful therapeutic
approach as well as a stricter follow-up should be recommended in
DTMC patients, at least in those showing a more aggressive subset
(multifocal lesions and lymph node involvement).
Overall, our advise is that the prediction of disease severity
cannot be based exclusively on lesion diameter.
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